This is a working overview of Lipodystrophy, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-02-18. Anything still debated is marked as such rather than presented as settled.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
Once reconstituted, the peptide is handled as a solution and is less stable than the lyophilized powder. Aqueous solutions are commonly kept cold and used within a defined period. Buffer composition and pH influence degradation rates, with extremes of acidity or alkalinity accelerating hydrolysis. Preservatives may be added in multi-dose formats to limit microbial growth. Freezing and thawing of solutions is generally avoided because it can cause precipitation or loss of activity.
Identity and purity are assessed by reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities. Mass spectrometry, often coupled to liquid chromatography, confirms molecular mass and detects chemical modifications. Peptide mapping and amino acid analysis can verify sequence integrity. Water content is measured by Karl Fischer titration, and residual solvents may be checked by gas chromatography. These methods together support batch-to-batch consistency and routine quality control.
Lyophilized tesamorelin is generally stored refrigerated at temperatures between 2 and 8 degrees Celsius. The solid form is comparatively stable when kept dry and protected from light. Moisture uptake can promote aggregation and degradation, so sealed containers with desiccant are common. Researchers typically avoid repeated temperature cycling, which may stress the peptide. Documentation accompanying reference materials usually specifies a shelf life under these conditions.
| Property | Value | Notes |
|---|---|---|
| Peptide class | Synthetic GHRH analogue | 44 residues; N-terminal trans-3-hexenoyl group |
| First approval year | 2010 | United States; HIV-associated abdominal fat accumulation |
| Administration route | Subcutaneous injection | Abdominal site; clinician-administered or self-injected |
| Common synonyms | TH9507; tesamorelin acetate | Development code and acetate salt form |
| Originator | Canadian biotechnology firm | Original developer and regulatory sponsor |
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
Tesamorelin is a synthetic peptide that acts as an analog of growth hormone-releasing hormone, a natural hypothalamic signal. Its sequence corresponds to the forty-four amino acid form of the human hormone, with a small acyl group attached near the amino terminus. That modification slows enzymatic breakdown and extends the time the peptide remains active in circulation. The compound was developed as a pharmacological way to raise endogenous growth hormone output rather than supplying the hormone directly.
After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.
Stability testing examines how the molecule changes under controlled stress. Thermal stress, light exposure, and extremes of pH are applied separately so that each degradation route can be attributed to a specific cause. The main observed changes are oxidation, deamidation, and aggregation into dimers or higher-order species. Accelerated studies at elevated temperature are used to estimate behavior over longer periods, though such extrapolation carries uncertainty. For a lyophilized powder, residual moisture and the choice of bulking agent strongly influence how quickly these changes appear.
Practical handling centers on limiting moisture, oxygen, and temperature excursions. Lyophilized material is generally held at or below minus twenty degrees Celsius, protected from light and kept sealed until use. Once reconstituted, solutions are typically kept cold and used within a short window because hydrolysis and microbial growth both accelerate in liquid form. Repeated freeze-thaw cycles are avoided, since they promote aggregation. Vial contents should be inspected for particulates and clarity before analysis, and working aliquots are prepared to reduce the number of times the stock is opened.
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
Assays for these markers differ in calibration and antibody specificity, so results from different platforms are not always interchangeable. Reported values can shift when a laboratory changes method, even without any biological change. Studies that span long periods or multiple sites often need cross-validation of assays. This methodological variability is a recognized limitation when comparing findings across published reports, and it remains a topic of ongoing standardization work.
Measuring the effect of a growth hormone-releasing hormone analogue requires markers that reflect pituitary output rather than the peptide itself. The two most frequently used are growth hormone and insulin-like growth factor 1. Growth hormone fluctuates sharply across the day and responds to sleep, stress, and meals, so isolated readings can be difficult to interpret. Insulin-like growth factor 1 changes more slowly and is often treated as the more stable integrated marker of axis activity.
Leukoreduced blood products are less likely to cause HLA alloimmunization (development of antibodies against specific blood types), febrile non-hemolytic transfusion reaction, cytomegalovirus infection, and platelet-transfusion refractoriness. Leukoreduction is performed using specialized filtration systems during blood processing, and in many countries it is routinely applied to most blood products before storage to reduce the risk of transfusion reactions and transmission of certain infections. Pathogen reduction treatment that involves, for example, the addition of riboflavin with subsequent exposure to UV light has been shown to be effective in inactivating pathogens (viruses, bacteria, parasites and white blood cells) in blood products. By inactivating white blood cells in donated blood products, riboflavin and UV light treatment can also replace gamma-irradiation as a method to prevent graft-versus-host disease (TA-GvHD).
In the second half of 1945, Thomas began reading for the BBC Radio programme, Book of Verse, broadcast weekly to the Far East. This provided Thomas with a regular income and brought him into contact with Louis MacNeice, a congenial drinking companion whose advice Thomas cherished. On 29 September 1946, the BBC began transmitting the Third Programme, a high-culture network which provided opportunities for Thomas. He appeared in the play Comus for the Third Programme, the day after the network launched, and his rich, sonorous voice led to character parts, including the lead in Aeschylus's Agamemnon and Satan in an adaptation of Paradise Lost. Thomas remained a popular guest on radio talk shows for the BBC, who regarded him as "useful should a younger generation poet be needed". He had an uneasy relationship with BBC management and a staff job was never an option, with drinking cited as the problem. Despite this, Thomas became a familiar radio voice and within Britain was "in every sense a celebrity". The publication of Deaths and Entrances in February 1946 was a major turning point for Thomas. Poet and critic Walter J. Turner commented in The Spectator, "This book alone, in my opinion, ranks him as a major poet".
=== Planned/unfinished designs === Focke-Wulf Fw 42 – twin-engined medium bomber project developed from the F 19, 1933. Focke-Wulf Ta 183 Huckebein – design for a jet-engined fighter, 1942. Focke-Wulf Fw 206 – planned commercial aircraft, 1940. Focke-Wulf Fw 238 – long-range bomber project (RLM airframe number 8-238 already used by Blohm und Voss) Focke-Wulf Fw 249 – large transport aircraft project; officially designated as Project 195. Focke-Wulf Fw 250 – twin-engine jet fighter project Focke-Wulf Fw 252 – single engine jet fighter Focke-Wulf Ta 254 – proposed version of the Ta 154 fighter. Focke-Wulf Fw 259 Frontjäger (concept) Focke-Wulf Fw 260 – 1960s VTOL airliner proposal Focke-Wulf Fw 261 – four-engine bomber/reconnaissance/U-boat support aircraft project Focke-Wulf Ta 283 – interceptor fighter project Focke-Wulf Fw 300 – proposed long-range version of Fw 200, 1941-1942. Focke-Wulf Ta 400 – Amerikabomber design competitor, never built, 1943. Focke-Wulf Fw P.03.10206 – series of long-range strategic bomber projects, 1944. Focke-Wulf Fw P.03.10221-15 – large capacity strategic transport, 1941. Focke-Wulf Fw P.03.10025 – A 1944 design with a swept wing, a forward-swept V-tail, and two pusher propellers at the rear. Focke-Wulf Fw 03.10251 – series of jet-engined night and bad weather fighters Focke-Wulf Fighter Project w/BMW803 – A 1941 design with a connected twin-boom tail, slightly swept-back wings, and two pusher propellers at the rear.
== Safety == DNCB induces a type IV hypersensitivity reaction in almost all people exposed to it, so it is used medically to assess the T cell activity in patients. This is a useful diagnostic test for immunocompromised patients. It can also be used to treat warts. DNCB can cause contact dermatitis.
Sources: en.wikipedia.org
, the Darcy friction factor (also called flow coefficient λ). For laminar flow in a circular pipe of diameter Dc, the friction factor is inversely proportional to the Reynolds number alone (fD = 64/Re) which itself can be expressed in terms of easily measured or published physical quantities (see section below). Making this substitution the Darcy–Weisbach equation is rewritten as
== External links == BURDEN of Resistance and Disease in European Nations – An EU-Project to estimate the financial burden of antibiotic resistance in European Hospitals Cochrane Wounds list of antimicrobials (PDF) National Pesticide Information Center Overview of the use of Antimicrobials in plastic applications The Antimicrobial Index – A continuously updated list of antimicrobial agents found in scientific literature (includes plant extracts and peptides)
=== EC 1.4.1 With NAD+ or NADP+ as acceptor === EC 1.4.1.1: alanine dehydrogenase EC 1.4.1.2: glutamate dehydrogenase EC 1.4.1.3: glutamate dehydrogenase (NAD(P)+) EC 1.4.1.4: glutamate dehydrogenase (NADP+) EC 1.4.1.5: L-amino-acid dehydrogenase EC 1.4.1.6: deleted, Now included with EC 1.21.4.1, D-proline reductase (dithiol) EC 1.4.1.7: serine 2-dehydrogenase EC 1.4.1.8: valine dehydrogenase (NADP+) EC 1.4.1.9: leucine dehydrogenase EC 1.4.1.10: glycine dehydrogenase EC 1.4.1.11: L-erythro-3,5-diaminohexanoate dehydrogenase EC 1.4.1.12: 2,4-diaminopentanoate dehydrogenase EC 1.4.1.13: glutamate synthase (NADPH) EC 1.4.1.14: glutamate synthase (NADH) EC 1.4.1.15: lysine dehydrogenase EC 1.4.1.16: diaminopimelate dehydrogenase EC 1.4.1.17: N-methylalanine dehydrogenase EC 1.4.1.18: lysine 6-dehydrogenase EC 1.4.1.19: tryptophan dehydrogenase EC 1.4.1.20: phenylalanine dehydrogenase EC 1.4.1.21: aspartate dehydrogenase EC 1.4.1.22: there is no overall consumption of NAD+ during the reaction. As a result, transfer of the enzyme from EC 4.3.1.12 was not necessary and EC 1.4.1.22 was withdrawn before being made official EC 1.4.1.23: valine dehydrogenase (NAD+) EC 1.4.1.24: 3-dehydroquinate synthase II EC 1.4.1.25: L-arginine dehydrogenase EC 1.4.1.26: 2,4-diaminopentanoate dehydrogenase (NAD+) EC 1.4.1.27: glycine cleavage system
The television announcer asks, "Need a tip when you're stuck in an awkward situation?" The fan passes around his "bucket of KFC", even though the commercial was intended for an Australian audience, which found its way to social media in the United States, prompting sharp disapproval. KFC Australia made a statement to the fact the commercial was "misinterpreted by a segment of people in the US" and it was a "light-hearted reference to the West Indian cricket team" and "The ad was reproduced online in the US without KFC's permission, where we are told a culturally-based stereotype exists, leading to the incorrect assertion of racism...We unequivocally condemn discrimination of any type and have a proud history as one of the world's leading employers for diversity". In May 2012, Greenpeace accused KFC of sourcing paper pulp for its food packaging from Indonesian rainforest wood. Independent forensic tests showed that some packaging contained more than 50 percent mixed tropical hardwood fiber, sourced from Asia Pulp & Paper (APP). APP said such fiber can be found in recycled paper, or: "It can also come from tree residues that are cleared, after a forest area has become degraded, logged-over or burned, as part of a sustainable development plan.
== Early life and education == Milan Mrksich (Serbian Cyrillic: Милан Мркшић) was born on August 15, 1968, to Serbian immigrants and raised in Justice, Illinois. He graduated from University of Illinois at Urbana-Champaign in 1989 with a B.S. in chemistry working in the laboratory of Steven Zimmerman on molecular tweezers. He completed his PhD in organic chemistry in 1994 from Caltech under chemist Peter B. Dervan. After graduate school, he was an American Chemical Society postdoctoral fellow at Harvard University under chemist George M. Whitesides before joining the faculty at the University of Chicago in 1996. He worked there for 15 years before joining the faculty at Northwestern University in 2011.
Sources: en.wikipedia.org
=== Israel === Israel declared a nationwide state of emergency, saying that the strikes on Iran were the largest that it had ever launched. Israeli schools and workspaces were closed and public gatherings were canceled. In the 40 days from the start of the war through the 8 April ceasefire, there were a total of 650 missile attacks from Iran to Israel, the majority of which carried cluster munitions. About 16 of the missiles that made it past Israeli missile defenses carried conventional warheads, while 50 had cluster munitions. The attacks killed a total of 24 people, all of them civilians, and resulted in more than 7,000 injuries. Of the 24 civilians killed, 14 were struck by conventional explosive warheads and 10 by cluster submunitions. Two of the deaths were inside a sheltered space, with the other fatalities being people in unprotected areas.
== Sources == Cooper, Tom; Grandolini, Albert; Delalande, Arnaud (2015). Libyan Air Wars, Part 1: 1973-1985. Helion & Company Publishing. ISBN 978-1-909982-39-0. Cooper, Tom; Grandolini, Albert; Delalande, Arnaud (2016). Libyan Air Wars, Part 3: 1986-1989. Helion & Company Publishing. ISBN 978-1-910294-54-3. Cooper, Tom & Weinert, Peter (2010). African MiGs: Volume I: Angola to Ivory Coast. Harpia Publishing LLC. ISBN 978-0-9825539-5-4.
== Extraction and representation == On an industrial scale, diallyl disulfide is produced from sodium disulfide and allyl bromide or allyl chloride at temperatures of 40–60 °C in an inert gas atmosphere; sodium disulfide is generated in situ by reacting sodium sulfide with sulfur. The reaction is exothermic and its theoretical efficiency of 88% has been achieved in practice.
{\displaystyle \alpha _{{\ce {H}}_{n-i}A^{i-}}={{[{\ce {H+}}]^{n-i}\displaystyle \prod _{j=0}^{i}K_{j}} \over {\displaystyle \sum _{i=0}^{n}{\Big [}[{\ce {H+}}]^{n-i}\displaystyle \prod _{j=0}^{i}K_{j}}{\Big ]}}}
Sources: en.wikipedia.org
It is a laboratory-made peptide of forty-four amino acids whose sequence matches human growth hormone-releasing hormone, with a modified amino terminus. The modification is a short unsaturated fatty acid chain attached to the first residue. This change slows enzymatic breakdown and lengthens the time the peptide stays active in circulation.
The clinical program was designed around HIV-associated lipodystrophy, a condition in which fat accumulates abnormally around the internal organs. Trials enrolled that specific population, so the evidence base covers it rather than the general population. Regulators approved the drug for the studied indication only, and promotion outside it is not permitted.
Growth hormone therapy supplies the finished hormone directly, while this peptide acts upstream and asks the pituitary to secrete its own. That difference means the response depends on a functioning pituitary and on the body's normal feedback loops. It also means the circulating hormone profile is pulsatile rather than a flat, injected level.
Refrigeration between 2 and 8 degrees Celsius is typical, with protection from moisture and light. Dry, sealed containers help maintain stability over the labeled shelf life. Temperature cycling is usually minimized.